Shopping Cart 0
Cart Subtotal
USD 0

Selecta Biosciences Inc (SELB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Selecta Biosciences Inc (Selecta Biosciences) is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company's pipeline products include SEL-212, SEL-403, SEL-302 and SEL-302. It utilizes synthetic vaccine particle (SVP) technology platform to incorporate a wide range of antigens and immunomodulators, for the development of products that induce antigen-specific tolerance or activate the immune system. Selecta Biosciences develops products for the treatment of infections, central nervous system diseases, cancer, allergies, cardiovascular diseases, autoimmunity, metabolic diseases, asthma and acute and chronic inflammatory conditions. The company collaborates with pharma companies to develop drugs for allergy and autoimmune diseases. Selecta Biosciences is headquartered in Watertown, Massachusetts, the US.

Selecta Biosciences Inc (SELB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Selecta Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Selecta Biosciences Raises USD38 Million in Series E Financing 12

Selecta Bioscience Raises USD6 Million in Venture Financing 14

Selecta Biosciences Raises More than USD20 Million in Venture Financing 15

Selecta Biosciences Raises USD4.4 Million in Venture Financing 17

Selecta Biosciences Raises USD6 Million in Venture Financing 18

Selecta Biosciences Raises USD5.3 Million in Venture Financing 19

Private Equity 20

Reinet Investments Invests USD4.43 Million in Selecta Biosciences 20

Partnerships 21

Selecta Biosciences Enters into Research Agreement with Genethon 21

Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 22

Licensing Agreements 23

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 23

Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 25

Selecta Biosciences Enters into Licensing Agreement with Massachusetts Eye and Ear Infirmary 27

Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 28

Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 29

Equity Offering 30

Selecta Biosciences Files Registration Statement to Raise Funds through Public Offering of Shares 30

Selecta Biosciences Raises USD50 Million in Private Placement of Shares and Warrants 31

Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 32

Selecta Biosciences Raises USD70 Million in IPO 34

Selecta Biosciences Inc-Key Competitors 36

Selecta Biosciences Inc-Key Employees 37

Selecta Biosciences Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 08, 2018: Selecta Biosciences announces second quarter 2018 financial results and provides corporate update 39

May 09, 2018: Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update 41

Mar 15, 2018: Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 42

Nov 07, 2017: Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update 44

Aug 11, 2017: Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update 46

May 11, 2017: Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update 48

Mar 27, 2017: Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 50

Corporate Communications 53

Sep 27, 2018: Selecta Biosciences names Carsten Brunn, Ph.D. as President and Chief Executive Officer 53

Jan 02, 2018: Massachusetts Selecta Biosciences' CEO to Retire at the End of 2018 54

Jan 02, 2018: Selecta Biosciences Announces CEO's Intent to Retire and Transition Plan 55

Oct 26, 2017: Selecta Biosciences Announces Important Additions to Senior Leadership Team 56

Product News 57

05/01/2017: Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy 57

Clinical Trials 58

Mar 12, 2018: Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma 58

Jan 09, 2018: Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-R 59

Jan 02, 2018: Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy 60

May 15, 2017: Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy 61

May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention 62

Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Celiac Disease Treatment 63

Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Selecta Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Selecta Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Selecta Biosciences Raises USD38 Million in Series E Financing 12

Selecta Bioscience Raises USD6 Million in Venture Financing 14

Selecta Biosciences Raises More than USD20 Million in Venture Financing 15

Selecta Biosciences Raises USD4.4 Million in Venture Financing 17

Selecta Biosciences Raises USD6 Million in Venture Financing 18

Selecta Biosciences Raises USD5.3 Million in Venture Financing 19

Reinet Investments Invests USD4.43 Million in Selecta Biosciences 20

Selecta Biosciences Enters into Research Agreement with Genethon 21

Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 22

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 23

Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 25

Selecta Biosciences Enters into Licensing Agreement with Massachusetts Eye and Ear Infirmary 27

Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 28

Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 29

Selecta Biosciences Files Registration Statement to Raise Funds through Public Offering of Shares 30

Selecta Biosciences Raises USD50 Million in Private Placement of Shares and Warrants 31

Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 32

Selecta Biosciences Raises USD70 Million in IPO 34

Selecta Biosciences Inc, Key Competitors 36

Selecta Biosciences Inc, Key Employees 37

Selecta Biosciences Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Selecta Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.